Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2012

View Archived Issues

Researchers at Acceleron Pharma patent new fusion proteins for cancer

First-in-man continuous levodopa/carbidopa study begins enrollment

Research collaboration for rare pediatric diseases established

PlGF as a novel biomarker for risk assessment in patients with light-chain amyloidosis

Nymox to commence study evaluating repeat injections of NX-1207

Recently reported data support phase II study of ALS-2200

Phase III perindopril/amlodipine fixed-dose combination study meets primary endpoint

Taiho presents data on TAS-2985, a novel inhibitor of FGFR

Antisense oligonucleotide drug targets alpha-1-antitrypsin deficiency

Bridged nucleic acid technology improves hypertriglyceridemia in mice

Klotho promoter hypermethylation linked to survival in glioblastoma multiforme

French group presents new agents for CML

Numedicus synthesizes novel AMPA receptor agonists

Scientists at Daiichi Sankyo prepare new 11-beta-HSD1 inhibitors

Adamed divulges novel fusion proteins for cancer

Researchers at Pfizer present new acetyl-CoA carboxylase inhibitors

New monoclonal antibodies for cancer presented by U.S. researchers

Paladin Labs launches sublingual grass pollen immunotherapy tablet in Canada

Novel agents for tuberculosis patented by GlaxoSmithKline

Botox approved for severe primary axillary hyperhidrosis in Japan

Everolimus approved in new TSC indications in Japan

Phase IIa trial begins of MediciNova's ibudilast

Pfizer launches Tygacil in Japan

Recruitment begins in pivotal phase IIb trial of GFT-505

FDA orphan drug designation granted to OXi-4503

EMA to begin formal review of macitentan MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...